Form 4: Promis Neurosciences Director Acquires Options in Company

Director Eugene Williams acquired options to purchase 40,000 common shares of Promis Neurosciences Inc. at an exercise price of $1.11, with vesting occurring over time.

Summary

• On October 3, 2024, Eugene Williams, a director of Promis Neurosciences Inc., was granted options to purchase 40,000 common shares.
• The exercise price of these options is $1.11 per share.
• 33% of the options vested immediately on October 3, 2024, with the remaining options vesting ratably over the next 24 months, contingent upon continued service.
• The options expire on October 3, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a standard director compensation practice. The option grant itself is neither overwhelmingly positive nor negative.

Positives

• The vesting schedule incentivizes continued service by the director.

Industry Context

This is a standard practice for compensating and incentivizing directors in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Option grants to directors are a common practice in the biotechnology industry, similar to companies like Biogen or Amgen, where stock options are used to align director compensation with company performance.
• The vesting schedule is also typical, often tied to continued service to ensure directors remain engaged and committed to the company's long-term success.

Stakeholder Impact

• The option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates